A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections

Author： Leflore S. Anderson P.L. Fletcher C.V.

ISSN： 0114-5916

Source： Drug Safety, Vol.23, Iss.2, 2000-08, pp. : 131-142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Herpes Simplex Virus Infections and Alzheimer's Disease: Implications for Drug Treatment and Immunotherapy

By Leissring M.A. Sugarman M.C. LaFerla F.M.

Drugs & Aging, Vol. 13, Iss. 3, 1998-09 ,pp. : 193-198

Adis International

Access to resources Recommend Favorite

Aciclovir: Development of resistance in herpes simplex virus type 1 infection in a neonate: case report

Reactions Weekly, Vol. 1, Iss. 1438, 2013-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Novel agents and strategies to treat herpes simplex virus infections

By Kleymann Gerald

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 2, 2003-02 ,pp. : 165-183

Informa Healthcare

Access to resources Recommend Favorite

Current Treatments of Muco-Cutaneous Herpes Simplex Virus Infections

Current Medicinal Chemistry - Anti-Infective Agents, Vol. 1, Iss. 1, 2002-01 ,pp. : 83-98

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Targets in Herpes Simplex and Epstein Barr Virus Infections

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 9, Iss. 2, 2009-04 ,pp. : 117-125

Bentham Science Publishers

Access to resources Recommend Favorite